论文信息 - Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. - 字舞流文

Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial.

T. Tankova | J. Buse | J. Frias | I. Lingvay | H. Bajaj | P. Auerbach | N. Tentolouris | A. Søndergaard | S. Macura | Y. Fukushima